Synaffix, a Lonza subsidiary, has signed licensing agreements with Boehringer Ingelheim and Mitsubishi Tanabe Pharma for advancing antibody-drug conjugate (ADC) programs. These deals reflect Synaffix's growing presence in the ADC space, with potential milestone payments and royalties involved.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing